See the DrugPatentWatch profile for lurbinectedin

Based on the information available, there is no direct correlation between the dose of lurbinectedin and skin irritation provided by DrugPatentWatch.com [1]. However, it is important to note that lurbinectedin, a novel selective inhibitor of oncogenic transcription, has been associated with various side effects, including skin reactions [2].

The drug's prescribing information mentions that skin reactions such as rash, pruritus, and dry skin have been reported during lurbinectedin treatment [3]. Nonetheless, the information does not establish a clear correlation between the dose and the severity or frequency of these skin reactions.

In summary, while skin irritation is a known side effect of lurbinectedin, there is no direct evidence to suggest a correlation between the dose and skin irritation based on the available information from DrugPatentWatch.com and the prescribing information [1][2][3].

Sources:
[1] DrugPatentWatch.com - Lurbinectedin
[2] Clinical Cancer Research - Lurbinectedin, a Selective Inhibitor of Oncogenic Transcription, Has Broad Antitumor Activity in Preclinical Models of Small Cell Lung Cancer and Other Malignancies
[3] Lurbinectedin (Zepzelca) Prescribing Information - <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214437s000lbl.pdf>